Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ethyol and Irinotecan in Metastatic Colorectal Cancer
NCT00003225Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jul 1997
- Primary completion
- Mar 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amifostine in colorectal cancer (CRC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Toxicity profile of Irinotecan and Ethyol at 12 weeks. Started Jul 1997; status: completed.
02
Drugs
amifostine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00003225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003225.